sars-cov-2-in-7

SARS-CoV-2-IN-7 demonstrates potent inhibition of viral replication in SARS-CoV-2-infected Vero E6 cells with an IC50 value of 844 nM.

SARS-CoV-2 nsp13-IN-7 (Compound 6r) is an inhibitor of SARS-CoV-2 nsp13, with an IC50 of 0.28 μM. This compound disrupts the helicase function of nsp13 by binding to its 5' RNA site and ATP binding site, and it serves as a lead compound for developing antiviral drugs targeting SARS-CoV-2 nsp13.

SARS-CoV-2 3CLpro-IN-7 is a reversible covalent inhibitor of the SARS-CoV-2 3CL protease, with an inhibitory concentration (IC50) of 1.4 µM.

SARS-CoV-2 Mpro-IN-7 (compound 6g) effectively inhibits the SARS-CoV-2 main protease (Mpro) with an IC50 value of 8.8 μM and exhibits a cytotoxic concentration (CC50) of 10 μM [1].

SARS-CoV-2-IN-72 (compound 12) is a potent allosteric inhibitor of the SARS-CoV-2 papain-like protease domain, capable of inducing degradation of NSP3.

SARS-CoV-2-IN-71 (compound 8h) is an effective inhibitor of SARS-CoV-2, demonstrating antiviral activity by targeting multiple stages of coronavirus replication. It exhibits its effects by simultaneously acting on 3CLpro and TMPRSS2.

SARS-CoV-2-IN-79 (Compound 5) is an inhibitor of SARS-CoV-2 with IC50 and CC50 values of 55 μg/mL and 311.6 μg/mL, respectively. It exhibits the highest antiviral activity against (hCoV-19/Egypt/NRC-03/2020). SARS-CoV-2-IN-79 is applicable for COVID-19 research.

SARS-CoV-2-IN-73 (compound 4) is an inhibitor of the SARS-CoV-2 RNA-dependent RNA polymerase (RdRp).

SARS-CoV-2-IN-74 (compound 30) is an epoxide inhibitor that suppresses the replication of SARS-CoV-2 in cells, with an EC68 value of 5 μM. It is applicable in coronavirus research.

SARS-CoV-2-IN-77 (compound 11e) is an inhibitor of cathepsin L and cathepsin S, with Ki values of 111 nM and 103 nM, respectively. It effectively inhibits SARS-CoV-2 in Calu-3 cells with an EC50 value of 38.4 nM and does not exhibit cytotoxicity.

SARS-CoV-2-IN-75 (compound 13), a chloroacetamide-based inhibitor, effectively suppresses cellular replication of SARS-CoV-2. It achieves a half-log reduction in viral titer (EC 68) at a concentration of 3 μM [1].

SARS-CoV-2-IN-76 (compound 1) operates as an inhibitor of both nsp14-viral cap N7 methyltransferase and PLpro in severe acute respiratory syndrome coronavirus (SARS-CoV-2) [1].

SARS-CoV-2-IN-78 (compound 3) functions as an inhibitor of nsp14 in SARS-CoV-2 and exhibits antiviral properties through its activity as an N7 methyltransferase [1].

Hydroxychloroquine sulfate (Acidum iopanoicum) inhibits plasmodial heme polymerase. It is a chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa.

Hydroxychloroquine (2-[[4-[(7-Chloroquinolin-4-yl)amino]pentyl](ethyl)amino]ethanol) (HCQ) is an alkalinizing lysosomatropic drug that acts by inducing apoptosis of renal cancer cells in vitro and inhibiting TLR7/9. It is a medication used to prevent and treat malaria, and it's also being studied as an experimental treatment for COVID-19.

SARS-CoV-2 Mpro-IN-29 (Compound 7) is an inhibitor of the SARS-CoV-2 main protease (Mpro), with an IC50 of 310 nM for Mpro and an EC50 of 0.5 μM in Vero cells. By binding to the active site of Mpro, it prevents the cleavage of viral polyproteins, exhibiting significant antiviral activity and enhanced metabolic properties. SARS-CoV-2 Mpro-IN-29 holds potential for research in SARS-CoV-2 antiviral drug development.

ZHAWOC25153 (Compound 17o) is an inhibitor of the SARS-CoV-2 papain-like protease (PLpro) with an IC50 of 7 μM. It demonstrates antiviral properties and is applicable for research in the field of anti-infective studies.

Mpro inhibitor N3 hemihydrate is a potent antagonist of the SARS-CoV-2 main protease (Mpro), with an EC50 of 16.77 μM against SARS-CoV-2. It specifically inhibits Mpro in various coronaviruses, including SARS-CoV, MERS-CoV, HCoV-229E (IC50 4.0 μM), FIPV (IC50 8.8 μM), and MHV-A59 (IC50 2.7 μM) [1][2].

MMT5-14 is a SARS-CoV-2 inhibitor. MMT5-14 showed 2- to 7-fold higher antiviral activity in four variants of SARS-CoV-2. By reducing premature hydrolysis in hamsters, MMT5-14 increased the prodrug concentration by 200- to 300-fold in the plasma and lungs but also enhanced lung accumulation of the active metabolite triphosphate nucleosides (NTP) by 5-fold.

Hydroxychloroquine Impurity E, an impurity found in Hydroxychloroquine, a synthetic antimalarial compound that also inhibits Toll-like receptor 7/9 (TLR7/9) signaling, has been shown to effectively inhibit SARS-CoV-2 infection in vitro [1] [2] [3].

Hydroxychloroquine Impurity F, an impurity in Hydroxychloroquine, is identified in the synthetic antimalarial agent known for its capability to inhibit Toll-like receptor 7/9 (TLR7/9) signaling. Additionally, Hydroxychloroquine demonstrates effective inhibition of SARS-CoV-2 infection in vitro [1] [2] [3].

SARS-CoV-2 nsp14-IN-3 (4975) is a potent inhibitor of the N7-Methyltransferase activity of SARS-CoV-2 nonstructural protein 14 (Nsp14), with an IC50 value of 3.5 μM [1].

RdRP-IN-7, a RNA-dependent RNA polymerase (RdRp) inhibitor, demonstrates efficacy against SARS-CoV-2 infection with an inhibitory concentration (IC50) of 8.2 μM and (IC90) of 14.1 μM, alongside a cytotoxic concentration (CC90) of 79.1 μM, rendering it suitable for antiviral research [1].

Hydroxychloroquine-d5 is a deuterated compound of Hydroxychloroquine. Hydroxychloroquine has a CAS number of 118-42-3. Hydroxychloroquine (HCQ) is an alkalinizing lysosomatropic drug that acts by inducing apoptosis of renal cancer cells in vitro and inhibiting TLR7/9. It is a medication used to prevent and treat malaria, and it's also being studied as an experimental treatment for COVID-19.